UBS Group upgraded shares of Jade Biosciences (NASDAQ:JBIO – Free Report) to a strong-buy rating in a report released on Monday morning,Zacks.com reports.
JBIO has been the topic of a number of other reports. Wedbush lifted their price target on shares of Jade Biosciences from $34.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Stifel Nicolaus set a $40.00 price target on Jade Biosciences in a research report on Friday, March 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Jade Biosciences in a research report on Monday, June 1st. BTIG Research increased their price target on Jade Biosciences from $39.00 to $74.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Finally, William Blair raised Jade Biosciences to a “strong-buy” rating in a research report on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Jade Biosciences presently has an average rating of “Buy” and a consensus price target of $47.13.
Check Out Our Latest Research Report on Jade Biosciences
Jade Biosciences Stock Performance
Jade Biosciences (NASDAQ:JBIO – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). As a group, research analysts forecast that Jade Biosciences will post -2.54 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new stake in Jade Biosciences in the 2nd quarter valued at $154,000. Legal & General Group Plc acquired a new position in shares of Jade Biosciences in the second quarter valued at $29,000. Rhumbline Advisers bought a new position in shares of Jade Biosciences in the second quarter valued at about $445,000. Russell Investments Group Ltd. acquired a new stake in shares of Jade Biosciences during the 2nd quarter worth about $31,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Jade Biosciences during the 2nd quarter worth about $114,000.
About Jade Biosciences
Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.
The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.
See Also
- Five stocks we like better than Jade Biosciences
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
